<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606252</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/18/0098</org_study_id>
    <secondary_id>2018-A01062-53</secondary_id>
    <nct_id>NCT03606252</nct_id>
  </id_info>
  <brief_title>Specialized Proresolving Mediators in Pneumocystis Jirovecii Pneumonia</brief_title>
  <acronym>INFLA-PCP</acronym>
  <official_title>Specialized Proresolving Mediators Evaluation in Pneumocystis Pneumonia Human Infection : Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate specialized proresolving mediators (SPM) concentrations for the
      first time in subjects infected with Pneumocystis jirovecii. SPM will be measured in blood
      and urine in patients with favourable or unfavourable outcome of Pneumocystis pneumonia and
      in patients colonized by Pneumocystis jirovecii. The hypothesis is that low levels of SPM in
      the blood could be predictive of a negative outcome of pneumocystosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pneumocystis pneumonia is a severe fungal disease threatening immunosuppressed subjects such
      as patients suffering from AIDS, oncohematological diseases or solid organ transplanted
      patients. The disease is characterized by an important inflammation in the infected lungs
      which is mainly responsible for lungs lesions. Despite an adequate treatment introduction,
      mortality is still around 20% which can not be explained by a treatment resistance.
      Specialized proresolving mediators (SPM), including lipoxins, maresins, protectins and
      resolvins, are newly described molecules implicated in the active process of inflammation
      resolution. The investigators hypothesis in this study is that high levels of SPM could be
      predictive of a good resolution of the harmful inflammation, thus a good evolution of the
      disease, in adequate pneumocystosis therapy conditions. On the contrary, low levels of SPM
      could be predictive of an unfavourable outcome despite a treatment targeting Pneumocystis
      jirovecii
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>14,15-DHET blood level at the inclusio</measure>
    <time_frame>Day 0</time_frame>
    <description>variation of 14,15-DHET blood level at inclusion between each group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>14,15-DHET blood level</measure>
    <time_frame>Day 7</time_frame>
    <description>variation of 14,15-DHET blood level at day 7 between each group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>14,15-DHET urine level</measure>
    <time_frame>Day 0 and Day 7</time_frame>
    <description>variation of 14,15-DHET urine level at inclusion ad day 7 between each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specialized Pro-Resolving Mediators in blood</measure>
    <time_frame>Day 0 and Day 7</time_frame>
    <description>Specialized Pro-Resolving Mediators in blood at inclusion and day 7 between each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specialized Pro-Resolving Mediators in urine</measure>
    <time_frame>Day 0 and Day 7</time_frame>
    <description>Specialized Pro-Resolving Mediators in urine at inclusion and day 7each between group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression levels of the SPM enzymes</measure>
    <time_frame>Day 0 and day 7</time_frame>
    <description>Expression levels of the enzymes implicated in SPM synthesis and catabolism in blood at D0 and day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory blood profile</measure>
    <time_frame>Day 0 and day 7</time_frame>
    <description>Inflammatory blood profile with composite criteria pro-inflammatory and anti-inflammatory cytokines levels measured by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cells profile</measure>
    <time_frame>Day 0 and day 7</time_frame>
    <description>immune cell proportions in blood measured by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Pneumonia, Pneumocystis</condition>
  <arm_group>
    <arm_group_label>pneumocystosis with favourable evolution</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with a favourable pneumocystosis outcome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pneumocystosis with unfavourable outcome</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with unfavourable pneumocystosis outcome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pneumocystis colonization</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>subject colonized by Pneumocystis jirovecii</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)</description>
    <arm_group_label>Pneumocystis colonization</arm_group_label>
    <arm_group_label>pneumocystosis with favourable evolution</arm_group_label>
    <arm_group_label>pneumocystosis with unfavourable outcome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>urine sampling</intervention_name>
    <description>2 urine sample (1 at J0 and 1 at J7)</description>
    <arm_group_label>Pneumocystis colonization</arm_group_label>
    <arm_group_label>pneumocystosis with favourable evolution</arm_group_label>
    <arm_group_label>pneumocystosis with unfavourable outcome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years old

          -  Patient with a social security cover.

          -  Free and informed oral consent given.

          -  Pneumocystis infection or colonization diagnosed on BAL (Broncho-alveolar liquid) or
             sputum at Toulouse University hospital Mycology laboratory.

          -  Adequate Pneumocystis therapy for infected patients (cotrimoxazole).

        Exclusion Criteria:

          -  individuals placed under juridical protection,

          -  individuals placed under guardianship, or supervision.

          -  Pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Berry, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toulouse University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine Berry, PHD</last_name>
    <phone>05 67 69 04 62</phone>
    <phone_ext>33</phone_ext>
    <email>berry.a@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Fédératif de Biologie (IFB), CHU - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Berry, PHD</last_name>
    </contact>
    <investigator>
      <last_name>Antoine BERRY, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier IRIART, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eléna CHARPENTIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume MARTIN-BLONDEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne HUYNH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nassim KAMAR, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud DEL BELLO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanislas FAGUER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain DIDIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elise NOEL-SAVINA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean RUIZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muriel PICARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ko Y, Jeong BH, Park HY, Koh WJ, Suh GY, Chung MP, Kwon OJ, Jeon K. Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients. J Crit Care. 2014 Jun;29(3):356-61. doi: 10.1016/j.jcrc.2013.12.005. Epub 2013 Dec 21.</citation>
    <PMID>24440053</PMID>
  </reference>
  <reference>
    <citation>Le Gal S, Robert-Gangneux F, Perrot M, Rouillé A, Virmaux M, Damiani C, Totet A, Gangneux JP, Nevez G. Absence of Pneumocystis dihydropteroate synthase mutants in Brittany, France. Diagn Microbiol Infect Dis. 2013 May;76(1):113-5. doi: 10.1016/j.diagmicrobio.2013.01.018. Epub 2013 Feb 20.</citation>
    <PMID>23433532</PMID>
  </reference>
  <reference>
    <citation>Le Faouder P, Baillif V, Spreadbury I, Motta JP, Rousset P, Chêne G, Guigné C, Tercé F, Vanner S, Vergnolle N, Bertrand-Michel J, Dubourdeau M, Cenac N. LC-MS/MS method for rapid and concomitant quantification of pro-inflammatory and pro-resolving polyunsaturated fatty acid metabolites. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Aug 1;932:123-33. doi: 10.1016/j.jchromb.2013.06.014. Epub 2013 Jun 15.</citation>
    <PMID>23831705</PMID>
  </reference>
  <reference>
    <citation>Gilroy DW, Edin ML, De Maeyer RP, Bystrom J, Newson J, Lih FB, Stables M, Zeldin DC, Bishop-Bailey D. CYP450-derived oxylipins mediate inflammatory resolution. Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):E3240-9. doi: 10.1073/pnas.1521453113. Epub 2016 May 25.</citation>
    <PMID>27226306</PMID>
  </reference>
  <reference>
    <citation>El Fane M, Sodqi M, Oulad Lahsen A, Chakib A, Marih L, Marhoum El Filali K. [Pneumocystosis during HIV infection]. Rev Pneumol Clin. 2016 Aug;72(4):248-54. doi: 10.1016/j.pneumo.2016.04.004. Epub 2016 Jun 24. Review. French.</citation>
    <PMID>27349824</PMID>
  </reference>
  <reference>
    <citation>Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol. 2014 Jul 1;307(1):C39-54. doi: 10.1152/ajpcell.00024.2014. Epub 2014 Apr 2.</citation>
    <PMID>24696140</PMID>
  </reference>
  <reference>
    <citation>Karsten E, Breen E, Herbert BR. Red blood cells are dynamic reservoirs of cytokines. Sci Rep. 2018 Feb 15;8(1):3101. doi: 10.1038/s41598-018-21387-w.</citation>
    <PMID>29449599</PMID>
  </reference>
  <reference>
    <citation>Keegan A, Charest K, Schmidt R, Briggs D, Deangelo DJ, Li B, Morgan EA, Pozdnyakova O. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. J Clin Pathol. 2018 Jul;71(7):653-658. doi: 10.1136/jclinpath-2017-204828. Epub 2018 Mar 27.</citation>
    <PMID>29588374</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>November 6, 2018</last_update_submitted>
  <last_update_submitted_qc>November 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumocystis jirovecii</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Specialized Proresolving Mediators</keyword>
  <keyword>Inflammation</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

